AIM-HIGH trial published in Lancet Molecular high-risk stage IA-IIA NSCLC as determined by 14-gene assay with improved survival with adjuvant chemo. It is not often we see survival curves like this in early stage lung cancer. thelancet.com/journals/lanre…

Viewpoint: The rise of social media and #AI in oncology has transformed scientific communication but also fuels bias, misinterpretation, and financial conflicts of interest. ja.ma/3UrqGLH Raffaele Giusti

🧪Medical cannabis in palliative care: evidence > hype. 📰RCT (Hardy 2025; Supportive Care in Cancer: Springer Journal rdcu.be/ex2xN) with THC:CBD 10/10 mg/ml → no benefit vs placebo; slight pain signal, more AEs. ⚠️Caution. substack.com/history/post/1… #Oncology #PalliativeCare #cannabis Substack

The Lancet Oncology: 80% of cancer drug trials in China (2017–2021) had design flaws that could affect results. 70% of #lungcancer trials take place in China, the US & Japan - leaving Europe reliant on results from elsewhere. This is why Europe must urgently strengthen trial

#Buprenorphine is not a first-line mandate in #cancer #pain. No comparative superiority over full µ-agonists; oncology guidance and WHO/EML keep morphine central. Policy should follow evidence—run pragmatic head-to-head trials now. #OncTwitter #PalliativeCare JAMA Oncology

One of oncology's paradoxes (🧵) Testicular germ cell tumors cure >90% with cisplatin, one of medicine’s greatest triumphs. But in mediastinal or extragonadal sites, survival drops to ~40–50%. 1. Why does one of the most curable cancers sometimes fail (~10-20%)?👇

Buprenorphine is Not a First-Line Mandate in Cancer Pain - Raffaele Giusti oncodaily.com/insight/raffae… JAMA Oncology #CancerPain #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews

EGFRm NSCLC—the indirect head-to-head we were waiting for. MARIPOSA (ami+laz) OS HR 0.75; median NR vs 36.7 mo. FLAURA2 (osi+CT) 47.5 vs 37.6 mo; HR 0.77. Similar OS gain, different trade-offs. “No chemo” ≠ “less toxicity”: toxicity redistributes. Cross-trial caution. #WCLC2025

🌍 WHO’s review of 89K cancer trials (1999–2022) shows most studies are concentrated in high-income countries, high-mortality cancers remain under-studied, ph 3 trials are rare, and pediatric and older pts are underrepresented. 💬WHO calls for a fairer, more inclusive, and

Might be the highest VTE rate I've seen in an RCT...😱😧😳 VTE "occurred in 40% of the participants in the amivantamab–lazertinib group and in 11% of... osimertinib group" nejm.org/doi/full/10.10…

Current USPSTF guidelines for cancer screening. American Cancer Society guidelines for breast ca annual screening starting age 40 can be an “option”. ACS also endorses colonoscopy at 45y/o for colon ca! For ⬆️ risk breast ca & CRC, consider earlier screening! #OncTwitter #MedTwitter

ONS/ASCO Guideline on the Management of Antineoplastic Extravasation ascopubs.org/doi/10.1200/OP…

NEJM 2025 (ALASCCA): Low-dose aspirin (160 mg) in PI3K-altered stage I–III CRC ↓ 3-yr recurrence (7.7% vs 14.1%, HR 0.49). 🔎 6,397 pts screened → 2,980 sequenced → 1,103 (37%) had PI3K-pathway mutations Hotspot exon 9/20: 17% Other PI3K/PTEN: 20% 📊 NNT: Colon II → weak (42)

Clinicians can enhance patient understanding by using numerical data instead of verbal probabilities, consistent denominators, absolute risk comparisons, and clear context for unfamiliar data types. ja.ma/42JRNGk

🫵🏻If you are involved in symptom management, quality of life, oncology–palliative care integration, or end-of-life care, these sessions are for you. 🗓️See you in Berlin—and bring your colleagues! ESMO - Eur. Oncology #ESMO25 #SupportiveCare #PalliativeCare #ESMODesignatedCentres #Oncology

Atezo + Tiragolumab in LA NSCLC after CT-RT ❌ Failed. #ESMO25

irAEs matter: costs and follow up care for long term effects #finalcialtoxicity #ESMO25

#ESMO25 Pegfilgrastim timing matters! In this randomized phase III trial (n=159, early-stage BC): Giving pegfilgrastim 72h after chemo — instead of 24–48h — cut bone pain by >50% without increasing neutropenia or FN risk.